A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Cannabidiol (Primary)
- Indications Dravet syndrome
- Focus Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 31 Jul 2017 Planned initiation date changed from 31 Aug 2017 to 30 Sep 2017.
- 31 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 31 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.